Extent of resection as an independent predictor of survival for patients with glioblastoma as defined by the new WHO 2021 classification.

doi:10.3171/2026.1.JNS25467

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Extent of resection as an independent predictor of survival for patients with glioblastoma as defined by the new WHO 2021 classification.

Journal of neurosurgery - 1 Sept 2026

Catalino Michael P, Suki Dima, Ballester Leomar, Andersen Clark R, Ramadoss Preeti, Prabhu Sujit S, Weinberg Jeffrey S, Poon Candice C, Cezayirli Phillip Cem, Brahimaj Bledi, McCutcheon Ian E, Ferguson Sherise D, Ene Chibawanye I, Kim Betty Y S, Raza Shaan M, Demonte Franco, Lang Frederick F

Abstract excerpt

OBJECTIVE: Extent of resection (EOR) has previously been demonstrated to have an impact on survival in patients with glioblastoma (GBM). However, with the World Health Organization (WHO) 2021 reclassification of GBMs based on IDH-mutation status, patients with "IDH-mutant GBMs," who typically survive long term, were reclassified as WHO grade 4 IDH-mutant astrocytomas and removed from the GBM taxonomy. Therefore,...

Read the complete abstract on PubMed

Topics

Humans
Glioblastoma
Brain Neoplasms
Female
Male

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Middle Aged

World Health Organization

Isocitrate Dehydrogenase

Adult

Aged

Mutation

Neurosurgical Procedures

Survival Rate

Prognosis

Source

Open in PubMed

Identifiers

PMID: 42398118
DOI: 10.3171/2026.1.JNS25467

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Extent of resection as an independent predictor of survival for patients with glioblastoma as defined by the new WHO 2021 classification.PMID 42398118Read ↗

Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.Semantic proximity Read ↗

Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4.Semantic proximity Read ↗

Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomas-A Single-Institution, Nine-Year Data.Semantic proximity Read ↗

[Molecular subtype-driven surgical concepts and clinical application in gliomas].Semantic proximity Read ↗

The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?Semantic proximity Read ↗

Decision system for extent of resection in WHO grade 3 gliomas: a Chinese Glioma Genome Atlas database analysis.Semantic proximity Read ↗

A comprehensive clinical, molecular, radiological, and surgical analysis for predicting prognosis in isocitrate dehydrogenase-mutant astrocytoma patients.Semantic proximity Read ↗

Imaging-Based Versus Pathologic Survival Stratifications of Diffuse Glioma According to the 2021 WHO Classification System.Semantic proximity Read ↗

Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis.Semantic proximity Read ↗

Supratotal Resection Versus Gross Total Resection for Isocitrate Dehydrogenase-Wildtype Glioblastoma and Grade 4 Isocitrate Dehydrogenase-Mutant Astrocytoma: Meta-Analysis of Individual Patient Data.Semantic proximity Read ↗

Novel insight into histological and molecular astrocytoma, IDH-mutant, Grade 4 by the updated WHO classification of central nervous system tumors.Semantic proximity Read ↗

The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.